Nestle SA CH-NESN
The Nestle circular said that the overall value of aimtune, including Nestle health science’s shares, was about $2.6 billion (about 17.8 billion yuan now).
Premium 1.74 times
After sorting out the snacks agents, we found that in the mergers and acquisitions announced by Nestle this year, except for one purchase of pet food, the other acquisitions were aimed at Nestle health science. The latter focuses on consumer services (including nutrition products, vitamins and over-the-counter drugs) and medical nutrition products (including special medical food).
Before today’s latest acquisition, Nestle Health Sciences has made four investments this year, including the announcement to acquire zenprep, a majority stake in vital proteins, an American collagen brand, and im HealthScience, a healthcare company, and a $200 million increase in aimtune.
据通报披露的交易条款显示，雀巢将通过全资子公司Société des Produits Nestlé S.A.（下称SPN）用现金收购Aimmune剩余所有的流通普通股，每股收购价为34.5美元。
Nestle said the offer still had to meet a series of conditions, including the acquisition of a sufficient number of ordinary voting shares in aimmune to approve the merger, the expiration or termination of the waiting period under the Hart Scott rodino antitrust Improvement Act of 1976, and other regulatory approvals. “Upon successful completion of the tender offer and other closing conditions, SPN’s wholly-owned subsidiary will merge with aimtune. Among them, aimmune will become the surviving company, and the outstanding shares not acquired by the offer will be converted at the consideration of US $34.50 per share. ” Nestle’s notice said.
Nestle said it planned to use existing funds to make the acquisition, which is expected to be completed in the fourth quarter of 2020, subject to customary conditions being met or exempted.
Nestle CEO Schneider
Food allergy Market
In fact, there is a huge potential consumer group and unmet demand behind Nestle’s “luxury spending”.
Palforzia is an oral immunotherapy (OIT) used to reduce the possible allergic reactions caused by accidental contact with peanuts. Specifically, children and adolescents aged 4 to 17 who have been diagnosed with peanut allergy can start to use palforzia treatment, and can continue treatment in individuals aged 4 and above. It is worth noting that in January this year, the FDA approved palforzia’s listing. Nestle reported that palforzia was “the first and only” FDA approved treatment for reducing the frequency and severity of peanut allergy in children aged 4 to 17. “In addition to prevention, palforzia provides a long-term solution for patients with peanut allergy.”. “The acquisition is an expansion of Nestle Health Sciences’ food allergy portfolio, creating a broader range of solutions for children with food allergies.” Nestle said it expects the acquisition to boost its organic growth in 2021 and increase its cash revenue in 2022 / 23. “Nestle health science is expected to double its sales by 2022, and is expected to reach 3.3 billion Swiss francs (now about 25 billion yuan) by 2020, based on 2 billion Swiss francs in 2014,” biggery told Reuters today.
“1 billion dollars” potential
This “confidence” in aimmune is not only because palforzia has occupied a promising blank market in advance, but also partly because consumers will spend a lot of money on taking palforzia. In the United States, aimmune is expected to price palforzia at $890 a month (equivalent to about 6229 yuan). And biggery told Reuters today that palforzia has the potential to achieve $1 billion in sales. “Palforzia has 12 years of exclusivity, followed by global promotion, and they will also provide a technical platform for other food allergies under development.”. As introduced by the snack generation, aimmune also has treatments for egg and other nut allergies (ar201 and ar301). These are also common allergenic foods.
Gr é gory Behar, Global CEO of Nestle Health Sciences
China’s anti allergy Market
If the deal is completed, it is not clear whether aimtune’s products will be introduced into China. But one thing is certain, anti allergy products are also Nestle’s market in China. Shortly before the announcement of the acquisition, Nestle had introduced the anti sensitive products of foreign companies participating in the investment into the Chinese market. As introduced by the snack agent, in July this year, Nestle Health Science announced the launch of its “spoonfulone spoonfulle” as an anti allergy supplementary food for infants and young children through cross-border e-commerce. In the future, it plans to enter the offline channel in China through general trade. The brand belongs to before brands, a company invested by Nestle Health Sciences in September last year, which is the technical authority on early childhood allergy prevention. Through this investment, Nestle Health Sciences has obtained the exclusive license right of its products outside the United States and has the right to purchase all the remaining equity of before brands in the future.